Oleanolic acid (OA), a pentacyclic triterpenoid molecule, that is present in our natural environment, is known to contain powerful anticancer properties. Because it has a low bioavailability, it has a low solubility in the aqueous phase, which is the reason why this is the case. The use of liposomal nanoformulations is an intriguing method that has the potential to be applied to provide OA with improved solubility and bioavailability during the delivery process. The current inquiry included the creation of OA nanoliposomes, as well as the investigation and modification of the physical and chemical features of these nanoliposomes. One of the most advantageous characteristics of OA nanoliposomes was its potential for use in medication delivery applications. The particle size range of these nanoliposomes was 174 nm and their zeta potential was -2.29 mV. Additionally, the percent entrapment efficacy of these nanoliposomes was 70.2%. Based on the cytotoxic efficiency of the OA-loaded liposomal nanoformulations against the MCF-7, A-549, and Hela cell lines, it was determined that this formulation possesses the ability to inhibit the proliferation of cancer cells. The current research endeavor has demonstrated that OA nanoliposomes have the potential to develop into promising nanoformulations for the treatment of cancer.